The health care system in California could save nearly $1.3 million a year with few adverse public health effects if it discontinued universal tuberculosis skin testing of children entering kindergarten, according to a new study by researchers at the University of California, San Francisco.
A family-based weight management program developed by researchers at Yale School of Medicine was more effective at reducing weight, body fat, body mass index (BMI) and insulin sensitivity than traditional clinic-based weight counseling.
Obese diabetes patients may lose weight effectively and decrease their use of glucose-controlling medications with a plate and cereal bowl with markers for proper portion sizes, revealed in a new study.
Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) announced study results comparing treatment with BYETTA(R) (exenatide) injection with insulin glargine in people with type 2 diabetes.
A plate and cereal bowl with markers for proper portion sizes appear to help obese patients with diabetes lose weight and decrease their use of glucose-controlling medications, according to a report in the June 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
Obese and very obese patients have a lower risk of dying after they have been treated for heart attacks than do normal weight patients, according to research published in the European Heart Journal.
Weight loss OTC diet pill Alli works with regular physical activity, exercise and good food with low calorie diet. The first and only over-the-counter product for weight loss approved by the Food and Drug Administration is available in US now.
Adding Glaxo’s Alli to diet and exercise can help people lose 50 per cent more weight than with dieting alone. This first U.S. sanctioned diet drug to be sold without a prescription is proving wildly popular.
Alli is the only FDA-approved weight-loss product available to overweight adults, 18 years or older, without a prescription. It combines a clinically-proven product with a comprehensive individualized action plan.
Sanofi-aventis announced that the U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee did not recommend approval of rimonabant (ZIMULTI(R)) to the US FDA for use in obese and overweight patients with associated risks factors.